Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
Authors
Keywords
-
Journal
BMJ-British Medical Journal
Volume -, Issue -, Pages l5221
Publisher
BMJ
Online
2019-09-19
DOI
10.1136/bmj.l5221
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selection of Endpoints in Clinical Trials: Trends in European Marketing Authorization Practice in Oncological Indications
- (2019) Anna Kordecka et al. VALUE IN HEALTH
- Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
- (2019) Emerson Y. Chen et al. JAMA Internal Medicine
- Surrogate endpoints in randomised controlled trials: a reality check
- (2019) Shaji Kumar et al. LANCET
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- Characteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications
- (2018) Steven Woloshin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- EMA recommended 35 new drugs in 2017
- (2018) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- 2017 FDA drug approvals
- (2018) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Do drugs offering only PFS maintain quality of life sufficiently from a patient’s perspective? Results from AVALPROFS (Assessing the ‘VALue’ to patients of PROgression Free Survival) study
- (2018) V. Jenkins et al. SUPPORTIVE CARE IN CANCER
- How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider
- (2018) Tony Tse et al. BMJ-British Medical Journal
- How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider
- (2018) Tony Tse et al. BMJ-British Medical Journal
- Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
- (2018) Jianrong Zhang et al. BMJ Open
- Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials
- (2018) Ariadna Tibau et al. JAMA Oncology
- A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
- (2018) Alyson Haslam et al. EUROPEAN JOURNAL OF CANCER
- Association between progression-free survival and patients’ quality of life in cancer clinical trials
- (2018) Thomas J. Hwang et al. INTERNATIONAL JOURNAL OF CANCER
- Reporting harms more transparently in trials of cancer drugs
- (2018) Bishal Gyawali et al. BMJ-British Medical Journal
- Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology
- (2018) Bruno Kovic et al. JAMA Internal Medicine
- Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union
- (2018) Jarno Hoekman et al. SOCIAL SCIENCE & MEDICINE
- Biases in Randomized Trials
- (2017) Mohammad Ali Mansournia et al. EPIDEMIOLOGY
- Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
- (2017) Huseyin Naci et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Unreported formal assessment of unblinding occurred in 4 of 10 randomized clinical trials, unreported loss of blinding in 1 of 10 trials
- (2017) Segun Bello et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks
- (2017) Joseph C Del Paggio et al. LANCET ONCOLOGY
- Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval
- (2017) HUSEYIN NACI et al. MILBANK QUARTERLY
- Conditional approval of medicines by the EMA
- (2017) Rita Banzi et al. BMJ-British Medical Journal
- The wider role of regulatory scientists
- (2017) Peter Doshi et al. BMJ-British Medical Journal
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study
- (2017) Agnes Dechartres et al. BMJ-British Medical Journal
- Conditional approval of medicines by the EMA
- (2017) Rita Banzi et al. BMJ-British Medical Journal
- The wider role of regulatory scientists
- (2017) Peter Doshi et al. BMJ-British Medical Journal
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study
- (2017) Agnes Dechartres et al. BMJ-British Medical Journal
- Bias in reporting of randomised clinical trials in oncology
- (2016) Francisco E. Vera-Badillo et al. EUROPEAN JOURNAL OF CANCER
- Relevance of randomised controlled trials in oncology
- (2016) Ian F Tannock et al. LANCET ONCOLOGY
- Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies
- (2016) Matthew J. Page et al. PLoS One
- Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits
- (2016) L. J. Fallowfield et al. SUPPORTIVE CARE IN CANCER
- Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
- (2016) Anthony J Hatswell et al. BMJ Open
- Allocation concealment in randomised controlled trials: are we getting better?: Table 1
- (2016) Laura Clark et al. BMJ-British Medical Journal
- Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study
- (2016) Matthew J. Page et al. PLOS MEDICINE
- Allocation concealment in randomised controlled trials: are we getting better?: Table 1
- (2016) Laura Clark et al. BMJ-British Medical Journal
- An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials
- (2016) Hemanth Kumar et al. JAMA Oncology
- The role of censoring on progression free survival: Oncologist discretion advised
- (2015) Vinay Prasad et al. EUROPEAN JOURNAL OF CANCER
- Influence of censoring on conclusions of trials for women with metastatic breast cancer
- (2015) Arnoud J. Templeton et al. EUROPEAN JOURNAL OF CANCER
- Approvals of drugs with uncertain benefit–risk profiles in Europe
- (2015) Rita Banzi et al. European Journal of Internal Medicine
- Risk of bias of randomized trials over time
- (2015) Ludovic Reveiz et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- The history and fate of the gold standard
- (2015) David S Jones et al. LANCET
- Avoidable waste of research related to inadequate methods in clinical trials
- (2015) Y. Yordanov et al. BMJ-British Medical Journal
- Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports
- (2015) M. Kohler et al. BMJ-British Medical Journal
- Why the drug development pipeline is not delivering better medicines
- (2015) Huseyin Naci et al. BMJ-British Medical Journal
- Why do cancer drugs get such an easy ride?
- (2015) D. W. Light et al. BMJ-British Medical Journal
- Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study
- (2015) I. Abraha et al. BMJ-British Medical Journal
- Avoidable waste of research related to inadequate methods in clinical trials
- (2015) Y. Yordanov et al. BMJ-British Medical Journal
- Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports
- (2015) M. Kohler et al. BMJ-British Medical Journal
- Why the drug development pipeline is not delivering better medicines
- (2015) Huseyin Naci et al. BMJ-British Medical Journal
- Why do cancer drugs get such an easy ride?
- (2015) D. W. Light et al. BMJ-British Medical Journal
- Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study
- (2015) I. Abraha et al. BMJ-British Medical Journal
- The Strength of Association Between Surrogate End Points and Survival in Oncology
- (2015) Vinay Prasad et al. JAMA Internal Medicine
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival
- (2015) Chul Kim et al. JAMA Internal Medicine
- Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy
- (2014) O. Bylicki et al. ANNALS OF ONCOLOGY
- Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors
- (2014) Asbjørn Hróbjartsson et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
- (2014) Nicholas S. Downing et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial publications
- (2014) Segun Bello et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Improving the Contribution of Regulatory Assessment Reports to Health Technology Assessments—A Collaboration between the European Medicines Agency and the European network for Health Technology Assessment
- (2014) Michael Berntgen et al. VALUE IN HEALTH
- Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports
- (2014) T. Jefferson et al. BMJ Open
- Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
- (2014) Tito Fojo et al. JAMA Otolaryngology-Head & Neck Surgery
- Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials
- (2013) Jelena Savović et al. ANNALS OF INTERNAL MEDICINE
- Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer
- (2013) F. E. Vera-Badillo et al. ANNALS OF ONCOLOGY
- How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers’ views
- (2013) G. Tafuri et al. ANNALS OF ONCOLOGY
- Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials
- (2013) R. Sridhara et al. CLINICAL CANCER RESEARCH
- Adverse Event Reporting in Cancer Clinical Trial Publications
- (2013) Shanthi Sivendran et al. JOURNAL OF CLINICAL ONCOLOGY
- Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews
- (2013) C. L. Vale et al. BMJ-British Medical Journal
- Differential dropout and bias in randomised controlled trials: when it matters and when it may not
- (2013) M. L. Bell et al. BMJ-British Medical Journal
- Searching for unpublished data for Cochrane reviews: cross sectional study
- (2013) J. B. Schroll et al. BMJ-British Medical Journal
- Completeness of Reporting of Patient-Relevant Clinical Trial Outcomes: Comparison of Unpublished Clinical Study Reports with Publicly Available Data
- (2013) Beate Wieseler et al. PLOS MEDICINE
- Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool
- (2013) Mark S. Corbett et al. Research Synthesis Methods
- Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols
- (2012) Rahul Mhaskar et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Progression-Free Survival: Meaningful or Simply Measurable?
- (2012) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?
- (2011) Francesco Pignatti et al. EUROPEAN JOURNAL OF CANCER
- Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?
- (2011) Eitan Amir et al. EUROPEAN JOURNAL OF CANCER
- Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
- (2011) Aaron S. Kesselheim JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology Trials
- (2009) Suman Bhattacharya et al. JOURNAL OF CLINICAL ONCOLOGY
- Issues in Using Progression-Free Survival When Evaluating Oncology Products
- (2009) Thomas R. Fleming et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolution of the Randomized Controlled Trial in Oncology Over Three Decades
- (2008) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
- Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study
- (2008) Lesley Wood et al. BMJ-British Medical Journal
- Reflections on Medical Oncology: 25 Years of Clinical Trials—Where Have We Come and Where Are We Going?
- (2007) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started